SecBot SecBot

PACB

PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
Nasdaq· Laboratory Analytical Instruments· Inc. DE· CIK 0001299130 Biotech & Drug DiscoveryGenomics & Gene Editing
$2.29 +0.18 (+8.42%)
Oct 26 4:00 PM ET · prev $2.11
Market cap
$640.3M
Small cap
Median target
$3.00
+31% · range $1.25–3.05
Next earnings
Nov 4
in 9 days · EPS est. −$0.13
1 year
+9.5%
from $2.09 · Oct 27
30 days
+33.8%
from $1.71
52-week range
$1.11–2.87
−20% from high · low Aug 12
Avg volume 20D
19.75M
Sep 30 spike 80.39M
Short interest
47.22M
≈15.2% of shares · −3.4%
Days to cover
3.0
at average volume
Insider net
−$2.2M
0 buyers · 3 sellers · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
Reddit crowd
58°
Warm · 2 mentions this week
SecBot read BEARISH 3 reports · 90 days
Balance 1 bearish · 0 bullish · 2 neutral oldest → newest, height = score
Avg score ·High conf. 1/3 ·Next Earnings date, Nov 4, 2026
Strongest BEARISH Director James R. Gibson II filed a Form 144 notice of intent to sell up to 661,815 shares of Pacific…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBEARISH

    3 insiders sold $2.2M.

  • InstitutionsMIXED

    Q2 2026: 21 added (0 new), 20 trimmed or exited.

  • EstimatesFALLING

    Current-quarter EPS estimate −$0.127 → −$0.131 over 90 days. 0 up, 1 down in 30 days.

  • Short sellersSTEADY

    Short interest −3.4% to 47.22M shares. 3.0 days to cover, ≈15.2% of shares.

  • TrendUPTREND

    34% above its 50-day average.

  • SocialQUIET

    Crowd 58° (warm) this week from 2 mentions: 1 bullish, 0 bearish. No setup call.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
BlackRock, Inc.ADD32,339,550$54.3M
Point72 Asset Management, L.P.DOUBLED4,787,300$8.0M
GOLDMAN SACHS GROUP INCDOUBLED3,229,887$5.4M
CITADEL ADVISORS LLCADD2,845,903$4.8M
Nuveen, LLCTRIM1,023,113$1.7M
RENAISSANCE TECHNOLOGIES LLCTRIM966,200$1.6M
UBS Group AGTRIM893,140$1.5M
Russell Investments Group, Ltd.ADD596,843$1.0M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

last action May 2026
12-month targets · 7 analysts

Price is inside the target range. Median implies +31%.Targets as of Oct 26, 2026.

Recent actions
DateFirmActionRating
May 11, 2026Barclays
MAINTAIN
MAINTAINUnderweight
Reddit
Crowd this week 58° Warm 1 bullish · 0 bearish
Mentions, 7 days 2 1 in posts · 1 in comments
Recent posts
r/pennystocks Bullish 1d ago
Three proteomics biotech penny stocks: NAUT, QSI and PACB
1 upvotes · 0 comments
Recent comments
r/pennystocks Neutral 1d ago
That PACB line barely twitching upward while NAUT ran 200%+ says a lot about where the speculative money is flowing. The Voyager platform doesn't even have a commercial product yet and traders are piling in like it's already printing cash. QSI catching a 78% bump while still sorting out launch delays is something. The ag and gene therapy pivot is smart but they need to actually ship before the runway gets too short.
All social signals and their track records

Insider ledger

Form 4
$0
bought · 0 insiders
$2.2M
sold · 3 insiders
DateInsiderTypeValue
Oct 6, 2026
Gibson James R II
See Remarks
SELL$2.1M
Oct 6, 2026
Gibson James R II
See Remarks
EXERCISE$590.0K
Aug 17, 2026
Van Oene Mark
See Remarks
SELL$30.4K
Aug 10, 2026
Van Oene Mark
See Remarks
AWARD489,130 sh
Aug 10, 2026
Van Oene Mark
See Remarks
AWARD1,967,888 sh
Jun 3, 2026
ORDONEZ KATHY
Director
AWARD223,492 sh
Jun 3, 2026
Ericson William W.
Director
AWARD223,492 sh
Jun 3, 2026
Gibson Christopher
Director
AWARD74,497 sh

Earnings setup

Estimates
Nov 4
reports in 9 days
−$0.13
EPS estimate, this quarter
−3%
estimate change, 90 days
0↑ 1↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.13-$0.14–-$0.12-1.9%$39.5M
Next Q-$0.13-$0.14–-$0.13-1.4%$43.0M
Current FY-$0.52-$0.53–-$0.50-0.8%$158.7M
Next FY🔒 Fresh data, subscribers only

Short side

FINRA· Sep 30, 2026
47,224,448
shares short
-3.4%
vs prior settlement
3.0
days to cover
≈15.2%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 19, 2026 Press
PacBio announced a multi-year strategic collaboration with Verily Health to integrate its HiFi long-read sequencing…
Impact 4/10
Oct 19, 2026 Contract
PacBio and Verily Health Announce Multi-Year Strategic Collaboration to Scale Long-Read Genomics for Biomedical AI
Verily Pre will connect PacBio HiFi Sequencing with governed cloud analysis, multimodal health data
Oct 6, 2026 SEC
Director James R. Gibson II filed a Form 144 notice of intent to sell up to 661,815 shares of Pacific Biosciences of…
144 — Impact 5/10
Oct 6, 2026 Press
PacBio announced a collaboration with TychoBio, an AI drug discovery company, to generate full-length RNA data using…
Impact 4/10
Oct 6, 2026 Insider
Gibson James R II sold 661,815 shares
See Remarks @ $3.11 ($2.1M)
Oct 6, 2026 Insider
Gibson James R II acquired via exercise 500,000 shares
See Remarks @ $1.18 ($590.0K)
Aug 17, 2026 Insider
Van Oene Mark sold 26,911 shares
See Remarks @ $1.13 ($30.4K)
Jun 30, 2026 Inst.
BlackRock, Inc. — ADD
32,339,550 shares ($54.3M)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 4, 2026
Earnings date
PACB Q3 2026 Earnings After Market Close — 2026-11-04
Recent
Oct 19, 2026
Contract
PacBio and Verily Health Announce Multi-Year Strategic Collaboration to Scale Long-Read Genomics for Biomedical AI
Verily Pre will connect PacBio HiFi Sequencing with governed cloud analysis, multimodal health data and AI-ready research workflows...
Oct 6, 2026
Contract
PacBio and TychoBio Collaborate to Train AI Models for Rare Disease RNA Therapeutics
PacBio Kinnex sequencing will generate full-length transcript data to help advance TychoBio’s drug discovery models PacBio Kinnex sequencing will…
Sep 3, 2026
Press release
PacBio to Participate in the Morgan Stanley 24ᵗʰ Annual Global Healthcare Conference
PacBio to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
Aug 5, 2026
Press release
PacBio Announces Faster Runs, Up to 50% More HiFi Data, and New Compliance Controls for the Vega system
Vega SPRQ-Nx chemistry to deliver up to 90 Gb per run at 40% lower cost per gigabase, with single-shift runs and new workflow controls for regulated…
Aug 5, 2026
Earnings date
PACB Q2 2026 Earnings After Market Close — 2026-08-05

SecBot reports

7 filings · 3 press releases · 1 bullish · 1 bearish · 5 neutral
All PACB filing & press-release reports (10)